HC Wainwright & Co. Maintains Buy on Pacira BioSciences, Lowers Price Target to $63
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Oren Livnat maintains a 'Buy' rating on Pacira BioSciences (NASDAQ:PCRX) but lowers the price target from $68 to $63.
August 04, 2023 | 12:46 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Despite the lowered price target, HC Wainwright & Co. maintains a 'Buy' rating on Pacira BioSciences, indicating continued confidence in the company.
The lowered price target might initially seem negative, but the maintained 'Buy' rating indicates that the analyst still sees potential in the company. This could lead to mixed reactions in the market, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100